Anti-angiogenic strategies in gastrointestinal malignancies.

作者: Jonathan Whisenant , Emily Bergstand

DOI: 10.1007/S11864-005-0044-8

关键词: Tumor progressionVascular endothelial growth factorMedicineNeuroendocrine tumorsAngiogenesisAnti angiogenicDiseaseColorectal cancerBevacizumabOncologyInternal medicine

摘要: Advances in our understanding of the mechanisms underlying tumor progression suggest that angiogenesis plays a key role gastrointestinal malignancies. Vascular endothelial growth factor (VEGF) has emerged as an important therapeutic target, and variety strategies to inhibit VEGF are under investigation. The approval bevacizumab for use patients with previously untreated metastatic colorectal cancer was based on clinical data suggesting is valid target this disease. As mature from ongoing trials, inhibitors treatment colon other malignancies will be more clearly defined. Additional information needed identify diseases stages most likely benefit anti-angiogenic agents optimal sequences combinations should studied.

参考文章(82)
Stefano Cascinu, Francesco Graziano, Vincenzo Catalano, Maria Pia Staccioli, Sandro Barni, Paolo Giordani, Maria Cristina Rossi, Anna Maria Baldelli, Pietro Muretto, Andrea Valenti, Giuseppina Catalano, Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clinical & Experimental Metastasis. ,vol. 18, pp. 651- 655 ,(2000) , 10.1023/A:1013133224044
David Lyden, Koichi Hattori, Sergio Dias, Carla Costa, Pamela Blaikie, Linda Butros, Amy Chadburn, Beate Heissig, Willy Marks, Larry Witte, Yan Wu, Daniel Hicklin, Zhenping Zhu, Neil R. Hackett, Ronald G. Crystal, Malcolm A.S. Moore, Katherine A. Hajjar, Katia Manova, Robert Benezra, Shahin Rafii, Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nature Medicine. ,vol. 7, pp. 1194- 1201 ,(2001) , 10.1038/NM1101-1194
Yehuda Z. Patt, Manal M. Hassan, Richard D. Lozano, Ajay K. Nooka, Isaac I. Schnirer, Jerome B. Zeldis, James L. Abbruzzese, Thomas D. Brown, Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. ,vol. 103, pp. 749- 755 ,(2005) , 10.1002/CNCR.20821
Shoshana Yakar, Lothar Hennighausen, Derek LeRoith, Ling Zhao, Yiping Wu, Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research. ,vol. 62, pp. 1030- 1035 ,(2002)
HX Chen, M Mooney, M Boron, L Grochow, J Zwiebel, D Vena, K Mosby, C Grandinetti, RS Kaplan, None, Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301) Journal of Clinical Oncology. ,vol. 22, pp. 3515- 3515 ,(2004) , 10.1200/JCO.2004.22.90140.3515
Yun Jeong Lim, Jong Kyun Lee, Cheol Keun Park, Sang Yong Song, Woo Young Jang, Hye Young Ha, Dong Il Park, Kyu Taek Lee, Seung Woon Paik, Byung Chul Yoo, Jong Chul Rhee, Prognostic value of VEGF in human pancreatic ductal adenocarcinoma. The Korean Journal of Internal Medicine. ,vol. 19, pp. 10- 14 ,(2004) , 10.3904/KJIM.2004.19.1.10
Eleanor J. Manseau, Brygida Berse, Kathi Tognazzi, Donald R. Senger, Lawrence F. Brown, Harold F. Dvorak, Robert W. Jackman, Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract Cancer Research. ,vol. 53, pp. 4727- 4735 ,(1993)
Paolo Giordani, Roberto Ghiselli, Maria Pia Staccioli, Vincenzo Catalano, Francesco Graziano, Vittorio Saba, Stefano Cascinu, Anna Maria Baldelli, Cristina Rossi, Giuseppina Catalano, Giampietro Gasparini, Pietro Muretto, Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clinical Cancer Research. ,vol. 6, pp. 2803- 2807 ,(2000)